{"id":"W4376609298","doi":"10.1038/s41591-023-02347-y","title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":270,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Clinical endpoint; Medicine; Pembrolizumab; Oncolytic virus; Oncology; Internal medicine; Hazard ratio; Phases of clinical research; Confidence interval; Clinical trial; Immunotherapy; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001747204,0.001343215,0.001544159,0.0003658796,0.000293015,0.0005718517,0.000571341,0.0007552239,0.0009455145],"category_scores_gemma":[0.0004337683,0.0003912654,0.0009477229,0.0002799762,0.0005752907,0.0005444973,0.0002914653,0.001632721,0.000281434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007267091,"about_ca_system_score_gemma":0.00103397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008907698,"about_ca_topic_score_gemma":0.002134457,"domain_scores_codex":[0.999612,0.0001994776,0.00002238463,0.00006874072,0.00003641928,0.00006087692],"domain_scores_gemma":[0.9997748,0.00002560058,0.00005699576,0.00002319298,0.00001714085,0.0001022775],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5218327,0.05996084,0.006633551,0.001323339,0.002575556,0.0003954146,0.0004844578,0.006307717,0.1514887,0.0005752305,0.004286395,0.2441361],"study_design_scores_gemma":[0.3707909,0.5942768,0.0118369,0.00005710494,0.0008927913,0.000469601,0.0000745319,0.003364295,0.01485696,0.0002832295,0.003047763,0.00004905723],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99615,0.00200313,0.0003729925,0.0002249777,0.00006915286,0.0005861075,0.0001773664,0.00004502657,0.0003712382],"genre_scores_gemma":[0.9927996,0.002408032,0.00163742,0.0003643338,0.0001422276,0.0009328885,0.0006746942,0.00002368423,0.001017097],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001747204,"threshold_uncertainty_score":0.00924021,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02117879798470894,"score_gpt":0.389980995708235,"score_spread":0.368802197723526,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}